View in EDS

Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.

Saved in:
Bibliographic Details
Title: Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Authors: Alexis AF; Weill Cornell Medicine, Dermatology, 211 East 80th St, 2nd Floor, New York, NY, 10075, USA. alexisa@med.cornell.edu., Bukhalo M; Arlington Dermatology, Rolling Meadows, IL, USA., Cook-Bolden FE; Park South Medical, Bronx, NY, USA., Del Rosso JQ; JDR Dermatology Research Center, LLC, Las Vegas, NV, USA., Draelos ZD; Dermatology Consulting Services, High Point, NC, USA., DuBois JC; DermResearch, Inc., Austin, TX, USA., Ferris LK; Department of Dermatology, University of North Carolina, Chapel Hill, NC, USA., Forman SB; ForCare Medical Center, Tampa, FL, USA., Kempers SE; Minnesota Clinical Study Center, Fridley, MN, USA., Kircik LH; Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Indiana Medical Center, Indianapolis, IN, USA.; Physicians Skin Care, PLLC and Skin Sciences, PLLC, Louisville, KY, USA., Lain E; Sanova Dermatology, Austin, TX, USA., Moore AY; Arlington Research Center, Arlington, TX, USA.; Baylor University Medical Center, Dallas, TX, USA., Pariser DM; Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA., Raoof J; Encino Research Center, Encino, CA, USA., Zirwas MJ; Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA., Seal MS; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Kato S; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Chu DH; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Krupa D; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Snyder S; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Burnett P; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Berk DR; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.
Source: American journal of clinical dermatology [Am J Clin Dermatol] 2026 Jan; Vol. 27 (1), pp. 189-198. Date of Electronic Publication: 2025 Nov 01.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1888 (Electronic) Linking ISSN: 11750561 NLM ISO Abbreviation: Am J Clin Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41175336
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Alexis+AF%22">Alexis AF</searchLink>; Weill Cornell Medicine, Dermatology, 211 East 80th St, 2nd Floor, New York, NY, 10075, USA. alexisa@med.cornell.edu.<br /><searchLink fieldCode="AU" term="%22Bukhalo+M%22">Bukhalo M</searchLink>; Arlington Dermatology, Rolling Meadows, IL, USA.<br /><searchLink fieldCode="AU" term="%22Cook-Bolden+FE%22">Cook-Bolden FE</searchLink>; Park South Medical, Bronx, NY, USA.<br /><searchLink fieldCode="AU" term="%22Del+Rosso+JQ%22">Del Rosso JQ</searchLink>; JDR Dermatology Research Center, LLC, Las Vegas, NV, USA.<br /><searchLink fieldCode="AU" term="%22Draelos+ZD%22">Draelos ZD</searchLink>; Dermatology Consulting Services, High Point, NC, USA.<br /><searchLink fieldCode="AU" term="%22DuBois+JC%22">DuBois JC</searchLink>; DermResearch, Inc., Austin, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ferris+LK%22">Ferris LK</searchLink>; Department of Dermatology, University of North Carolina, Chapel Hill, NC, USA.<br /><searchLink fieldCode="AU" term="%22Forman+SB%22">Forman SB</searchLink>; ForCare Medical Center, Tampa, FL, USA.<br /><searchLink fieldCode="AU" term="%22Kempers+SE%22">Kempers SE</searchLink>; Minnesota Clinical Study Center, Fridley, MN, USA.<br /><searchLink fieldCode="AU" term="%22Kircik+LH%22">Kircik LH</searchLink>; Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Indiana Medical Center, Indianapolis, IN, USA.; Physicians Skin Care, PLLC and Skin Sciences, PLLC, Louisville, KY, USA.<br /><searchLink fieldCode="AU" term="%22Lain+E%22">Lain E</searchLink>; Sanova Dermatology, Austin, TX, USA.<br /><searchLink fieldCode="AU" term="%22Moore+AY%22">Moore AY</searchLink>; Arlington Research Center, Arlington, TX, USA.; Baylor University Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Pariser+DM%22">Pariser DM</searchLink>; Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA.<br /><searchLink fieldCode="AU" term="%22Raoof+J%22">Raoof J</searchLink>; Encino Research Center, Encino, CA, USA.<br /><searchLink fieldCode="AU" term="%22Zirwas+MJ%22">Zirwas MJ</searchLink>; Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA.<br /><searchLink fieldCode="AU" term="%22Seal+MS%22">Seal MS</searchLink>; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kato+S%22">Kato S</searchLink>; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.<br /><searchLink fieldCode="AU" term="%22Chu+DH%22">Chu DH</searchLink>; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.<br /><searchLink fieldCode="AU" term="%22Krupa+D%22">Krupa D</searchLink>; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.<br /><searchLink fieldCode="AU" term="%22Snyder+S%22">Snyder S</searchLink>; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.<br /><searchLink fieldCode="AU" term="%22Burnett+P%22">Burnett P</searchLink>; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.<br /><searchLink fieldCode="AU" term="%22Berk+DR%22">Berk DR</searchLink>; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100895290%22">American journal of clinical dermatology</searchLink> [Am J Clin Dermatol] 2026 Jan; Vol. 27 (1), pp. 189-198. <i>Date of Electronic Publication: </i>2025 Nov 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>100895290 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1888 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211750561%22">11750561 </searchLink><i>NLM ISO Abbreviation: </i>Am J Clin Dermatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41175336
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40257-025-00984-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 189
    Titles:
      – TitleFull: Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Alexis AF
      – PersonEntity:
          Name:
            NameFull: Bukhalo M
      – PersonEntity:
          Name:
            NameFull: Cook-Bolden FE
      – PersonEntity:
          Name:
            NameFull: Del Rosso JQ
      – PersonEntity:
          Name:
            NameFull: Draelos ZD
      – PersonEntity:
          Name:
            NameFull: DuBois JC
      – PersonEntity:
          Name:
            NameFull: Ferris LK
      – PersonEntity:
          Name:
            NameFull: Forman SB
      – PersonEntity:
          Name:
            NameFull: Kempers SE
      – PersonEntity:
          Name:
            NameFull: Kircik LH
      – PersonEntity:
          Name:
            NameFull: Lain E
      – PersonEntity:
          Name:
            NameFull: Moore AY
      – PersonEntity:
          Name:
            NameFull: Pariser DM
      – PersonEntity:
          Name:
            NameFull: Raoof J
      – PersonEntity:
          Name:
            NameFull: Zirwas MJ
      – PersonEntity:
          Name:
            NameFull: Seal MS
      – PersonEntity:
          Name:
            NameFull: Kato S
      – PersonEntity:
          Name:
            NameFull: Chu DH
      – PersonEntity:
          Name:
            NameFull: Krupa D
      – PersonEntity:
          Name:
            NameFull: Snyder S
      – PersonEntity:
          Name:
            NameFull: Burnett P
      – PersonEntity:
          Name:
            NameFull: Berk DR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2026 Jan
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1179-1888
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: American journal of clinical dermatology
              Type: main
ResultId 1